1st Patient Enrolled in Phase 2a Trial Testing AT-1501 in ALS
Novus Therapeutics has enrolled the first patient in its Phase 2a trial of AT-1501 in adults with…
Articles by Forest Ray PhD
Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS
Catalent Biologics has agreed to manufacture NurOwn, the cell-based therapy by BrainStorm Cell Therapeutics being evaluated in a soon-to-conclude…
Lack of Testosterone Metabolite in Spinal Fluid May Be Linked to ALS
A metabolite of testosterone, dihydrotestosterone (DHT), is found at significantly lower levels in the cerebrospinal fluid of people…
Phase 2 Study of Pegcetacoplan in Recently Diagnosed Patients Opens
A Phase 2 and potentially pivotal study investigating pegcetacoplan (APL-2) as a potential treatment for amyotrophic lateral sclerosis (ALS) is…
FightMND Grant Awards Further Work Into ALS, Other Motor Neuron Diseases
Three grants given researchers at two centers in Australia will advance work into ways of preserving nerve cells in people…
Novus Acquires Anelixis, Plans to Move AT-1501 Into Phase 2 Trial for ALS
Novus Therapeutics has acquired Anelixis Therapeutics and its portfolio, including the antibody AT-1501, a potential treatment for amyotrophic…
Investigational Treatment IPL344 Safely Slows ALS Progression in Small Phase 1/2a Trial
IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and…
Helixmith Planning Phase 2 Trial of Engensis, Potential Gene Therapy for ALS
Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential…
RESCUE-ALS Phase 2 Trial Completes Enrollment Ahead of Schedule
Patient enrollment is now complete for the Phase 2 clinical trial of Clene Nanomedicine‘s …
Cause of WWII-era ALS Cluster on Guam May Be Younger Cycad Seeds
Younger cycad seeds can contain more toxins than older seeds, and their widespread consumption by people on occupied Guam during…